Hyperuricemia and Left Ventricular Diastolic Function

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

67 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-08-01

Study Completion Date

2018-04-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Metabolic syndrome and hyperuricemia were both associated with inflammation, leading to diversities of cardiovascular disease such as left ventricular diastolic dysfunction, but the relationship among these entities remained unclear. The aim of the present study focuses on the association among hyperuricemia, diastolic dysfunction and inflammatory biomarkers in apparently healthy individuals with metabolic syndrome

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mechanisms of Diuretic Resistance in Heart Failure, Aim 3

NCT06209359

Heart Failure Diuretic Resistance

RECRUITING PHASE1

Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure

NCT02546583

Heart Failure

COMPLETED PHASE1

Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients

NCT01503671

Heart Failure

UNKNOWN PHASE4

Diagnosis/Pathophysiology of Glucocorticoid Remediable Aldosteronism Hypertension

NCT00005394

Cardiovascular Diseases Hypertension Heart Diseases

COMPLETED

Community-based Microalbuminuria Screening in Patients With Hypertension

NCT03596840

Hypertension Microalbuminuria

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Apparently healthy individuals with metabolic syndrome were prospectively and consecutively enrolled since August 2017. Blood samples were obtained after participants are fasting for at least 12 hours, including serum uric acid, high-sensitivity C-reactive protein, high-sensitivity interleukin-6, tumor necrotizing factor alpha, fasting glucose, glycosylated hemoglobin, insulin, lipid profile, creatinine, alanine aminotransferase, sodium, potassium, and calcium. All echocardiographic parameters were measured in accordance with the American Society of Echocardiography guidelines.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperuricemia Metabolic Syndrome Left Ventricular Diastolic Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normouricemia

Serum uric of 7mg/dl or less in men or 6mg/dl or less in women

hyperuricemia

Intervention Type DIAGNOSTIC_TEST

serum uric acid of 7mg/dl or more in men or 6mg/dl or more in women

Hyperuricemia

Serum uric of 7mg/dl or more in men or 6mg/dl or more in women

hyperuricemia

Intervention Type DIAGNOSTIC_TEST

serum uric acid of 7mg/dl or more in men or 6mg/dl or more in women

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

hyperuricemia

serum uric acid of 7mg/dl or more in men or 6mg/dl or more in women

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age between 20 to 75 years
2. Metabolic syndrome

Exclusion Criteria

1. Left ventricular ejection fraction \<40%
2. Severe valvular heart disease
3. Significant structure heart diseases such as hypertrophic, dilated, infiltrative or restrictive cardiomyopathy, or congenital heart disease
4. Persistent or chronic atrial fibrillation
5. Status post cardiac surgery, including coronary artery bypass surgery of valve intervention
6. Status post intra-cardiac device implantation
7. Chronic obstructive pulmonary disease
8. Severe anemia
9. An obvious systemic disease that interferes left ventricular diastolic dysfunction such as acute coronary syndrome

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No